Last updated on July 2015

Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas Aeruginosa Wound Infections in Burned Patients


Brief description of study

The objective of PHAGOBURN is to assess tolerance and efficacy of local bacteriophage treatment of E. coli or P. aeruginosa wound infections in burned patients.

Detailed Study Description

PHAGOBURN is a Phase I/II clinical trial randomized, multicentric, open label, standard of care (Silver Sulfadiazine) controlled aiming at assessing tolerance and efficacy of local bacteriophage treatment of wound infections due to E. coli or P. aeruginosa in burned patients using Pherecydes Pharma anti-Escherichia coli and anti-Pseudomonas aeruginosa bacteriophage cocktails GMP produced. This project is a European Research & Development (R&D) project funded by the European Commission under the 7th Framework Programme for Research and Development. This project is involving 7 clinical sites in EU.

Clinical Study Identifier: NCT02116010

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Serge Jennes, MD

Hopital Militaire Reine Astrid
Brussel, Belgium
  Connect »

Anne-Françoise Rousseau, MD

CHU Sart-Tilman
Liege, Belgium
  Connect »

Patrick Jault, MD

H pital d'instruction des arm es Percy
Clamart, France
  Connect »

François Ravat, MD

Centre hospitalier ST Joseph et St Luc
Lyon, France
  Connect »

Yok-Ai Que, Mer, MD

Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
  Connect »